MedDataX Logo

Primary Liver Cancer Cohort of South China

NCT ID: NCT03297255

Last Updated: 2017-09-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

4000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-01-01

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This longitudinal observational cohort study was designed to investigate factors that influencing the occurrence and long-term survival of patients with primary liver cancer. Basic informations and detailed diagnosis informations (AJCC/TNM stage, MELD score, Child-Pugh score, and BCLC stage) were collected by professional doctors. Clinical outcomes (death, recurrence, and metastasis) will be followed up every two years after therapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary liver cancer (PLC) is highly malignant with high mortality which is particularly popular in China. Many factors are believed to associate with the occurrence and prognosis of liver cancer. This longitudinal observational cohort study was designed to investigate factors that influencing the occurrence and long-term survival of patients with primary liver cancer.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Liver Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Primary Liver Cancer; Cohort Study

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age 18-80 years
* consistent with primary liver cancer diagnostic criteria
* first diagnosis (from diagnosis to admission interval of less than a month)
* did not do any treatment of liver cancer

Exclusion Criteria

* refused to participate in this study
* suffering from more than two kinds of primary tumors
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Huilian Zhu

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Huilian Zhu

Professor

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Zhu Huilian, Professor

Role: STUDY_CHAIR

Sun Yat-sen University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Zhu Huilian, Professor

Role: CONTACT

Phone: +86 20 87331811

Email: [email protected]

Fang Aiping

Role: CONTACT

Phone: 020-87335875

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Chen Minshan, Professor

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Liu ZY, Yishake D, Fang AP, Zhang DM, Liao GC, Tan XY, Zhang YJ, Zhu HL. Serum choline is associated with hepatocellular carcinoma survival: a prospective cohort study. Nutr Metab (Lond). 2020 Mar 30;17:25. doi: 10.1186/s12986-020-00445-z. eCollection 2020.

Reference Type DERIVED
PMID: 32256673 (View on PubMed)

Liu ZY, Tan XY, Li QJ, Liao GC, Fang AP, Zhang DM, Chen PY, Wang XY, Luo Y, Long JA, Zhong RH, Zhu HL. Trimethylamine N-oxide, a gut microbiota-dependent metabolite of choline, is positively associated with the risk of primary liver cancer: a case-control study. Nutr Metab (Lond). 2018 Nov 20;15:81. doi: 10.1186/s12986-018-0319-2. eCollection 2018.

Reference Type DERIVED
PMID: 30479648 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SYS-2013

Identifier Type: -

Identifier Source: org_study_id